Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | Cytogenetic risk stratification in FLT3-mt NPM1-negative AML undergoing alloSCT in remission

Arnon Nagler • 1 Feb 2021
TCT 2021
Acute Myeloid Leukemia Leukemia

Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, outlines the role of cytogenetic risk stratification in FLT3-mutated NPM1-negative patients with AML undergoing allogeneic stem cell transplantation (alloSCT) in remission. In these patients, cytogenetic risk is significantly associated with outcome and therefore an important prognosticator in FLT3-mutated, NPM1-negative AML patients undergoing alloSCT. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Arnon Nagler

2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:21
Trends in alloSCT for good-risk AML: a longitudinal study
Arnon Nagler • 9 Dec 2023
2:15
GvHD prophylaxis post-alloSCT: PTCy versus ATG
Arnon Nagler • 9 Dec 2023
2:13
Haploidentical SCT for the treatment of secondary AML
Arnon Nagler • 9 Dec 2023

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals